Shannon–Erne Waterway

Univar Solutions Publishes 2021 Environmental, Social and Governance (ESG) Report

Retrieved on: 
Thursday, June 23, 2022
Workforce, Living Together, Growing Together, Culture, Multimedia, Univar Solutions, ESG, HRC, OXO-biodegradation, Transport, Shannon–Erne Waterway, COVID-19, Security (finance), Injury, Hazardous waste, Corporate Equality Index, Forward-looking statement, Company, Accident, Human Rights Campaign, Securities Act of 1933, Securities Exchange Act of 1934, Health, Electricity, Social, DEI, Energy Independence and Security Act of 2007, Carbon, Solution, U.S. Securities and Exchange Commission, View, NYSE, Terminology, Goal, Social Security Government Pension Offset, Lithium, Renewable energy, Risk management

DOWNERS GROVE, Ill., June 23, 2022 /PRNewswire/ -- Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global commodity and specialty chemical and ingredient distributor and provider of value-added specialty services, today released its 2021 ESG report, which is available through the Univar Solutions website at https://www.univarsolutions.com/sustainability.

Key Points: 
  • Details progress toward ESG goals to 2025 and beyond, including key emissions
    DOWNERS GROVE, Ill., June 23, 2022 /PRNewswire/ -- Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global commodity and specialty chemical and ingredient distributor and provider of value-added specialty services, today released its 2021 ESG report, which is available through the Univar Solutions website at https://www.univarsolutions.com/sustainability .
  • Univar Solutions Publishes 2021 Environmental, Social and Governance (ESG) Rep
    The report tracks Univar Solutions' progress against its ESG targets over the past year, including the successful completion of its initial five-year goals, launched in 2017, and ongoing progress toward its recently launched ESG goals to 2025 and beyond.
  • Throughout 2021, Univar Solutions accelerated the integration of its new ESG goals across the Company globally.
  • By incorporating sustainability into its operating strategies, processes and culture, Univar Solutions is well positioned to meet its future goals.

Univar Solutions Publishes 2021 Environmental, Social and Governance (ESG) Report

Retrieved on: 
Thursday, June 23, 2022
Workforce, Living Together, Growing Together, Culture, Univar Solutions, ESG, HRC, OXO-biodegradation, Transport, Shannon–Erne Waterway, COVID-19, Security (finance), Injury, Hazardous waste, Corporate Equality Index, Forward-looking statement, Company, Accident, Human Rights Campaign, Securities Act of 1933, Securities Exchange Act of 1934, Health, Electricity, DEI, Energy Independence and Security Act of 2007, Carbon, Solution, U.S. Securities and Exchange Commission, NYSE, Terminology, Goal, Lithium, Renewable energy, Risk management

DOWNERS GROVE, Ill., June 23, 2022 /PRNewswire/ -- Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global commodity and specialty chemical and ingredient distributor and provider of value-added specialty services, today released its 2021 ESG report, which is available through the Univar Solutions website at https://www.univarsolutions.com/sustainability.

Key Points: 
  • Details progress toward ESG goals to 2025 and beyond, including key emissions
    DOWNERS GROVE, Ill., June 23, 2022 /PRNewswire/ -- Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global commodity and specialty chemical and ingredient distributor and provider of value-added specialty services, today released its 2021 ESG report, which is available through the Univar Solutions website at https://www.univarsolutions.com/sustainability .
  • The report tracks Univar Solutions' progress against its ESG targets over the past year, including the successful completion of its initial five-year goals, launched in 2017, and ongoing progress toward its recently launched ESG goals to 2025 and beyond.
  • Throughout 2021, Univar Solutions accelerated the integration of its new ESG goals across the Company globally.
  • By incorporating sustainability into its operating strategies, processes and culture, Univar Solutions is well positioned to meet its future goals.

CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics

Retrieved on: 
Monday, May 23, 2022
WES, Physician, NGS, Company, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Lists of diseases, U.S. Securities and Exchange Commission, European Board of Ophthalmology, Nasdaq, Genetic testing, Patient, Polymorphism (computer science), Nature, Degenerative disease, European Society for Medical Oncology, WGS, Whole genome sequencing, Genetics, Legislation, Research, European Society of Human Genetics, Neurodegeneration, Industry, European Journal, SNV calling from NGS data, Medical genetics, Technology, Organization, Risk, European Journal of Human Genetics, Instability, Ministry of Science and Technology (India), Shannon–Erne Waterway, DNA sequencing, SEC, Growth, Sequence, Laboratory, Diagnosis, Security (finance), Outline, Human genetics, GLOBE, Medical imaging, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 23, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, as part of a consortium of organizations in genetics, announced the release of updated recommendations for Whole Genome Sequencing (WGS) in the rare disease diagnostic setting. The report, which was published in the European Journal of Human Genetics, promotes standardized application of WGS – minimizing diagnostic delay to promote better health outcomes.

Key Points: 
  • At that time, the guidelines predominantly focused on Whole Exome Sequencing (WES) and gene panels to identify Single Nucleotide Variants (SNVs) and insertions/deletions (indels).
  • EuroGentest, Horizon2020s Solve-RD team, CENTOGENE, and organizations throughout Europe teamed up to evaluate and update the 2016 NGS guidelines to outline the clinical application of WGS.
  • Whole Genome Sequencing has been increasingly popular due to its advanced nature of capturing disease-causing variants in a single test.
  • CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository of over 650,000 individuals representing over 120 different countries.